Navigation Links
Denosumab reduces burden of giant-cell tumor of the bone
Date:9/21/2012

PHILADELPHIA Treatment with denosumab, a drug targeted against a protein that helps promote bone destruction, decreased the number of tumor giant cells in patients with giant-cell tumor of the bone, and increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

"Giant-cell tumor of the bone is a rare tumor that affects mostly young people," said Sant P. Chawla, M.D., director of the Santa Monica Oncology Center, Santa Monica, Calif. "Radical surgery is currently the only treatment option. In our study, the use of denosumab allowed patients to avoid radical surgery and prevented recurrence. We hope that in the future, its use may make it possible to avoid surgery completely."

Giant-cell tumor of the bone is a benign tumor characterized by giant cells that are positive for the protein RANK ligand, which helps promote bone destruction. Currently, the only treatment option for patients with giant-cell tumor of the bone is surgery. However, patients who undergo surgery often have recurrent disease or significant morbidity, such as amputation. In addition, 25 to 30 percent of patients with this tumor have to undergo joint replacements.

Chawla and colleagues conducted this phase II study to explore the mechanism of action of denosumab, an inhibitor of RANK ligand, in the treatment of giant-cell tumor of the bone.

Twenty adult patients with recurrent or unresectable giant-cell tumor of the bone were treated with subcutaneous denosumab every four weeks. After treatment, all 20 of the patients had a decrease in giant cells of 90 percent or greater, an indicator of a reduction of tumor burden. In addition, results indicated that 65 percent of the patients had new bone growth in areas where the RANK ligand had previously caused bone destruction.

"A majority of patients with giant-cell tumor of the bone are young and have to get joint replacements, which last 15 to 20 years before a repeat surgery is needed," Chawla said. "Now, we hopefully can do minimal surgery, avoiding a joint replacement and recurrence."

One of the next steps in evaluating denosumab for giant-cell tumor of the bone is a much larger, multinational study that is currently enrolling patients. In addition, Chawla hopes to evaluate the use of denosumab as a presurgery, or neoadjuvant, treatment as well.

"In the future we hope to investigate giving the drug prior to surgery to see the effect it has, then remove the tumor and evaluate the pathological response," Chawla said.

This study was funded by Amgen.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
2. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
3. Automated breast ultrasound dramatically reduces physician interpretation time
4. NIH study finds sigmoidoscopy reduces colorectal cancer rates
5. Surgical removal of abdominal fat reduces skin cancer in mice
6. Long-term ICS use reduces pleural effusion in patients with CAP
7. Regional anesthesia reduces complications and death for hip fracture patients
8. Surgical sling reduces risk of weakened bladder control after prolapse surgery, U-M study says
9. Single embryo transfer reduces the risk of perinatal mortality in IVF
10. HPV vaccine reduces infection, even in unvaccinated
11. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... Sideline Products participated in the World Horse Expo held in ... and his production crew. Tom Seay’s program “Best of America by Horseback” is ... Sidekicks will be featured on April 6, 2017. After the broadcast, the clip will ...
(Date:2/22/2017)... ... February 22, 2017 , ... The first-ever National ... organizations, advocates, and individuals join together to increase recognition about the risks of ... lives. , “Today we mark a nationwide movement to raise awareness about a ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as ... one of a small number of neurosurgeons in Michigan performing minimally invasive back ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... company, launched a new media platform connecting healthcare technology professionals and other key ... followed by a quarterly publication starting on March 1, announced Michael J. Hennessy, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the Athens Home Show ... Georgia. , A shift from Super-Sod’s simple Athens Home Show booth of 2016, this ... grass seed plant manager Chris Roquemore constructed furniture from recycled pallet wood at the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)...  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: ... fourth quarter and full year 2016 financial results on Thursday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at 4:30 ... be obtained as follows: Thursday, March 2 ...
(Date:2/22/2017)... N.J. , Feb. 22, 2017  Andre, DiMino, ... technology-based developer and manufacturer of innovative technologies and products, ... results reported on February 21, 2017 in the Company,s ... . ADMT CEO Andre, DiMino stated "During ... our business plan by devoting a larger portion of ...
(Date:2/22/2017)... -- Ultra Clean Holdings, Inc. (Nasdaq: UCTT), a leading ... for the semiconductor capital equipment, flat panel, medical, ... results for the fourth quarter and fiscal year ... a year of extraordinary growth for UCT. Total ... together with continued focus on operational excellence resulted ...
Breaking Medicine Technology: